Author

A. Krstic

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Research Focus:gene regulatory network inference· 3 Organism:mouse· 3 Approach:statistical model· 3 Research Focus:development & morphogenesis· 2 Research Focus:differential expression· 2

Frequent Co-Authors

C. Gustafsson· 3 shared R. Mansson· 3 shared S. Kharazi· 3 shared T. Bouderlique· 3 shared M. Kierczak· 2 shared N. Frengen· 2 shared N. Kadri· 2 shared W. Kolch· 2 shared

Activity by Year

2018-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

C. Gustafsson

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Kinase Suppressor of RAS 1 (KSR1) maintains the transformed phenotype of BRAFV600E mutant human melanoma cells

Z. Liu, A. Krstic, A. Neve, N. Rauch, K. Wynne, H. Cassidy, A. McCann, E. Kavanagh, B. McCann, A. Blanco, J. Rauch, W. Kolch

This study shows that KSR1 is essential for maintaining the transformed phenotype of BRAFV600E mutant melanoma cells by promoting cell survival and inhibiting senescence and apoptosis.

bioRxiv · Aug 16, 2022Cancer Biology

Analysis of alternative mRNA splicing in vemurafenib-resistant melanoma cells

H. Bokharaie, W. Kolch, A. Krstic

The paper analyzes alternative mRNA splicing in vemurafenib-resistant melanoma cells and finds that combining multiple AS analysis tools improves accuracy and identifies biologically relevant splicing events.

bioRxiv · Mar 16, 2022Cancer Biology

FOXO dictates initiation of B cell development and myeloid restriction in common lymphoid progenitors

L. Pena-Perez, S. Kharazi, N. Frengen, A. Krstic, T. Bouderlique, J. Hauenstein, M. He, E. Somuncular, X. Li Wang, C. Dahlberg, C. Gustafsson, A.-S. Johansson, J. Walfridsson, N. Kadri, P. S. Woll, , R. Mansson

The paper shows that FOXO1 and FOXO3 are essential for B cell development and myeloid restriction in common lymphoid progenitors, with their combined loss causing developmental block and loss of B cell lineage.

bioRxiv · Jan 21, 2022Immunology

FOXO1 and FOXO3 cooperatively regulate innate lymphoid cell development

T. L. Thanh, J. Norskov, L. P. Perez, S. Kharazi, A. Krstic, S. Meinke, L. Schmied, N. Frengen, Y. Heshmati, M. Kierczak, T. Bouderlique, A. Wagner, C. Gustafsson, B. Chambers, A. Achour, , N. Kadri

This study identifies FOXO1 and FOXO3 as cooperative regulators of innate lymphoid cell development and maturation, affecting lineage specification and response to IL-15.

bioRxiv · Jan 13, 2021Cell Biology

Mutational, transcriptional and viral shedding dynamics of the marine turtle fibropapillomatosis tumor epizootic

K. Yetsko, J. Farrell, M. R. Stammnitz, L. Whitmore, J. Whilde, C. B. Eastman, D. Rollinson Ramia, R. Thomas, A. Krstic, P. Linser, S. Creer, G. Carvalho, B. Burkhalter, E. P. Murchison, C. Schnitzler, D. J. Duffy

This study investigates the mutational, transcriptional, and viral shedding dynamics of fibropapillomatosis in marine turtles, revealing molecular differences between tumor types and identifying potential therapeutic targets.

bioRxiv · Feb 4, 2020 · PreprintCancer Biology

The concerted action of E2-2 and HEB is critical for early lymphoid specification

T. Bouderlique, L. Pena Perez, S. Kharazi, M. Hils, X. Li, A. Krstic, A. de Paepe, C. Schachtrup, C. Gustafsson, D. Holmberg, K. Schachtrup, R. Mansson

This study shows that E2-2 and HEB are essential for early lymphoid specification, as their disruption blocks B-cell and T-cell development while leaving other hematopoietic lineages unaffected.

bioRxiv · Nov 9, 2018Immunology